2.38%
6.64%
-0.78%
2.36%
27.51%
235.48%
489.54%
AI Spotlight on LLY
Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance.Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc.Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Market Data
| Last Price | 823.23 |
| Change Percentage | 2.38% |
| Open | 808.41 |
| Previous Close | 804.08 |
| Market Cap ( Millions) | 781505 |
| Volume | 2115005 |
| Year High | 972.53 |
| Year Low | 643.17 |
| M A 50 | 778.42 |
| M A 200 | 839.71 |
Financial Ratios
| FCF Yield | -0.28% |
| Dividend Yield | 0.63% |
| ROE | 65.15% |
| Debt / Equity | 218.54% |
| Net Debt / EBIDTA | 221.76% |
| Price To Book | 52.09 |
| Price Earnings Ratio | 88.62 |
| Price To FCF | -358.69 |
| Price To sales | 19.12 |
| EV / EBITDA | 64.67 |
News
- Jan -29 - Eli Lilly Stock's Correction Brings Opportunity
- Jan -29 - Next Generation Donors' Charitable Giving Interests and Approaches Examined in New Study From Indiana University Lilly Family School of Philanthropy and DAFgiving360
- Jan -28 - Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
- Jan -28 - What Does the Future Hold for Eli Lilly?
- Jan -27 - Winners and losers in Monday's DeepSeek shake-up
- Jan -25 - Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
- Jan -25 - Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
- Jan -25 - Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
- Jan -24 - Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
- Jan -24 - Why Eli Lilly Stock Topped the Market Today
- Jan -24 - Thurgood Marshall College Fund receives $25 million grant from Lilly Endowment for HBCU capacity building
- Jan -24 - 3 Richly Valued Stocks I'll Be Watching Like a Hawk in 2025
- Jan -24 - 2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
- Jan -23 - Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
- Jan -23 - Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
- Jan -23 - The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's
- Jan -23 - My Top 5 Stocks to Buy in Early 2025
- Jan -22 - Eli Lilly (LLY) Rises Higher Than Market: Key Facts
- Jan -22 - This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
- Jan -22 - GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Human Pharmaceutical Products
Expected Growth : 7.9 %
What the company do ?
Eli Lilly and Company's human pharmaceutical products include medications for diabetes, cancer, mental health, and other diseases, such as Humulin, Cialis, and Prozac.
Why we expect these perspectives ?
Eli Lilly's Human Pharmaceutical Products segment growth of 7.9% is driven by strong demand for diabetes treatments, particularly Trulicity and Jardiance, as well as growth in oncology products, such as Verzenio and Cyramza. Additionally, the company's immunology portfolio, including Taltz and Olumiant, contributes to the segment's growth.
Eli Lilly And Company Products
| Product Range | What is it ? |
|---|---|
| Humulin | Humulin is a brand of insulin medication used to treat diabetes. It is a human insulin analog that helps to regulate blood sugar levels. |
| Alimta | Alimta is a chemotherapy medication used to treat malignant pleural mesothelioma and non-small cell lung cancer. |
| Cymbalta | Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) used to treat depression, anxiety, and chronic pain. |
| Forteo | Forteo is a parathyroid hormone used to treat osteoporosis in postmenopausal women and men. |
| Humalog | Humalog is a fast-acting insulin analog used to treat diabetes. |
| Jardiance | Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. |
| Olumiant | Olumiant is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis. |
| Portrazza | Portrazza is a monoclonal antibody used to treat non-small cell lung cancer. |
| Reyvow | Reyvow is a serotonin receptor agonist used to treat acute migraine. |
| Trulicity | Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. |
| Verzenio | Verzenio is a cyclin-dependent kinase (CDK) 4/6 inhibitor used to treat breast cancer. |
Eli Lilly and Company's Porter Forces
Threat Of Substitutes
Eli Lilly and Company faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs in the market.
Bargaining Power Of Customers
The bargaining power of customers is low due to the lack of price sensitivity and the importance of patented drugs in the treatment of chronic diseases.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers of raw materials and the company's ability to negotiate prices.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry, including the need for significant investments in research and development and regulatory approvals.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of established players in the pharmaceutical industry, leading to intense competition for market share and pricing pressure.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 70.08% |
| Debt Cost | 3.95% |
| Equity Weight | 29.92% |
| Equity Cost | 5.80% |
| WACC | 4.50% |
| Leverage | 234.18% |
Eli Lilly and Company : Quality Control
Eli Lilly and Company passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PFE | Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin … |
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Pfizer
A-Score
1-Year Total Return ->
🥉
Gilead Sciences
A-Score
1-Year Total Return ->
4
Merck
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
